現代牙科(03600.HK)預期2021年淨利同比增加約225.0%至243.5%
格隆匯3月11日丨現代牙科(03600.HK)公吿,集團預期:(i)2021年財政年度的收益將介於29億港元至30億港元,同比增加約32.4%至37.0%;(ii)2021年財政年度的未計利息、税項、折舊及攤銷前盈利將介於6.2億港元至6.4億港元,同比增加約40.1%至44.6%; (iii)2021年財政年度的純利將介於3.5億港元至3.7億港元,同比增加約225.0%至243.5%。
集團2021年財政年度的收益、EBITDA及純利增加,主要由於全球牙科行業穩健復甦及牙科器材供應商行業因為疫情及客户使用口腔掃瞄儀而加速整合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.